等待开盘 02-04 09:30:00 美东时间
-0.479
-1.79%
Moderna Reports Five-Year Data Showing mRNA-4157 and Keytruda Cut Melanoma Recurrence Risk by 49% Moderna Inc. and Merck have announced median five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, which evaluated adjuvant treatment with intismeran autogene in combination with
01-27 23:57
BRIEF-New England Journal Of Medicine Publishes Phase 3 Ascent-04/Keynote-D19 Results Jan 21 (Reuters) - Gilead Sciences Inc GILD.O : NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES PHASE 3 ASCENT-04/KEYNOTE-D19 RESULTS SUPPORTING TRODELVY® PLUS KEYTRUDA® AS A POTENTIAL NEW STANDARD OF CARE IN FIRST-LINE
01-22 06:18
VanEck has new ETFs that aim to minimize tracking error by eliminating artificial limits on leading holdings.
2025-08-26 21:17